Company K Partners

Company K Partners is a principal investment firm based in Gyeonggi-do, South Korea, established in 2006. The firm focuses on investments in various industries, including cultural content, electronic components, computer technology, machinery, broadcasting, arts, sports, and leisure. While primarily investing in South Korea, particularly in the regions of Seoul, Gyeongnam, and Gyeonggi, Company K Partners also seeks opportunities in the information technology and healthcare sectors.

Jae Won D

Principal

241 past transactions

MADDE

Series A in 2025
MADDE is a technology company specializing in advanced 3D printing solutions. It has developed a proprietary process that uses silicon carbide powder in 3D printers, enabling the creation of diverse forms and components. This innovation has significant implications for various industries, including manufacturing, aerospace, and energy. By reducing part count, lead time, and costs, MADDE's technology contributes to streamlined production processes and enhanced efficiency.

Prazer Therapeutics

Series B in 2025
Prazer Therapeutics is a biotechnology company dedicated to developing novel therapeutics for patients suffering from intractable diseases, particularly neurodegenerative and refractory inflammatory conditions. The company employs innovative drug design methodologies, including rational molecular drug design and next-generation protein degradation technology, to create effective treatments. By focusing on areas of unmet medical need, Prazer Therapeutics aims to advance drug development and provide solutions for diseases that currently lack effective therapies.

Imagoworks

Series C in 2024
Imagoworks offers a Web-based dental CAD solution using AI, streamlining the digital workflow for dental professionals. Imagoworks currently offers Dentbird Crown, which automatically generates optimal crown designs with a single click and without any software installation required.

Hyperaccel

Series A in 2024
HyperAccel specializes in hardware solutions tailored for AI application development. The company designs AI-specific semiconductors, optimizing memory bandwidth usage and enhancing cost efficiency, thereby facilitating real-time task completion for businesses.

Baropharm

Venture Round in 2024
BaroPharm is an e-commerce platform focused on enhancing individual care through the sale of pharmaceutical products. It operates an integrated pharmacy management platform that streamlines the drug ordering process for pharmacies. This platform consolidates multiple wholesale sites, enabling pharmacies to order medicines from a single interface rather than navigating several individual sites. By simplifying the procurement process, BaroPharm aims to improve efficiency and accessibility within the pharmaceutical distribution landscape.

Qutope

Series A in 2024
QuTope is a manufacturer specializing in chemical and biomaterials, focusing on the development of a laser-based platform for isotope separation and production. The company's innovative technology aims to provide high-quality isotope materials for various applications, including biochemical, nanoelectronics, and quantum technologies. By utilizing advanced techniques, QuTope enables clients to access affordable and effective products that support advancements in quantum sensors and quantum computing. Through its commitment to innovation, QuTope positions itself as a key player in the specialized materials sector.

Makestar

Series D in 2024
Makestar is a platform that specializes in K-culture content, facilitating a connection between Hallyu stars and their global fanbase. The company enables artists and production companies to share their creative visions while offering fans the opportunity to engage directly with celebrities. Through its music crowdfunding platform, Makestar supports various projects related to Korean pop music, allowing fans to participate in the content production process and interact with their favorite stars. This unique approach not only fosters a sense of community among fans but also aids artists in expanding their reach and advancing their careers internationally.

Bio Design Lab

Series B in 2024
Bio Design Lab is a biotechnology company focused on the development of biopharmaceutical products, specifically in the areas of gene, cell, and immunotherapies. The company employs systems-level genetic and genomic design strategies to create potent drugs aimed at addressing a range of diseases. By utilizing advanced methodologies, Bio Design Lab aims to enhance the efficiency of drug development processes for healthcare organizations, ultimately contributing to the creation of effective therapeutic solutions.

Diden Robotics

Seed Round in 2024
Diden Robotics is a pioneering company that develops and deploys advanced robotic solutions for industrial environments. Their flagship product is a quadruped robot, designed to navigate complex terrains and perform automated inspections and tasks in hazardous conditions, thereby enhancing safety and efficiency for its clients.

Baropharm

Venture Round in 2024
BaroPharm is an e-commerce platform focused on enhancing individual care through the sale of pharmaceutical products. It operates an integrated pharmacy management platform that streamlines the drug ordering process for pharmacies. This platform consolidates multiple wholesale sites, enabling pharmacies to order medicines from a single interface rather than navigating several individual sites. By simplifying the procurement process, BaroPharm aims to improve efficiency and accessibility within the pharmaceutical distribution landscape.

Velymonkeys

Series B in 2024
Blimonkids has created and run its own retail platform to aid the expansion of Korean cosmetics in India. In particular, it offers a one-stop service for the introduction of Korean beauty products into India, distribution, and sales, as well as marketing and sales, through its own mall, Maccaron.

EYEQ Lab

Series B in 2024
EYEQ Lab is an engineering service company specializing in the development of power semiconductors. The company aims to revolutionize the power semiconductor industry by leveraging the expertise and advanced technologies of its skilled team. EYEQ Lab's semiconductor applications span various sectors, including solar energy, autonomous vehicles, high-speed battery chargers, medical equipment, and aerospace. Through its innovative solutions, EYEQ Lab enables customers to stay at the forefront of power semiconductor technology.

Space Lintech

Series A in 2024
Space Lintech provides novel medical research, development, and manufacture in the microgravity environment of satellites and space stations.

Meditherapy

Series A in 2024
Meditherapy Co. is a retailer specializing in health and beauty products aimed at enhancing skincare for the face and body. The company has developed a comprehensive platform that offers a range of skincare items, including eye creams, wrinkle rollers, face masks, and serums. By consolidating various skincare needs into a single platform, Meditherapy enables customers to easily access and purchase a diverse array of beauty products tailored to their individual requirements.

Raion Robotics

Seed Round in 2024
Raion Robotics specializes in manufacturing quadruped robots for industrial use. Their flagship product, the Libo 2, leverages reinforcement learning technology to enable walking robots for applications in surveillance, disaster relief, and exploration, with potential in defense, construction, and logistics sectors.

Wirobotics

Series A in 2024
WIRobotics is a developer of innovative wearable robot technology aimed at enhancing musculoskeletal health. The company's products are designed to fit closely to the body, utilizing flexible robotic mechanisms and high-performance actuators. This technology not only reduces physical strain on users but also facilitates active movement. Additionally, WIRobotics incorporates data-driven task monitoring and analysis to quantify labor intensity, providing valuable insights for organizations seeking to improve workplace conditions and promote smart work care. By focusing on the intersection of robotics and health, WIRobotics addresses the physical demands of work environments, ensuring safer and more efficient operations.

AlgoCare

Series A in 2024
AlgoCare is an AI-driven healthcare startup that provides specialized Nutrition as a Service (NaaS) to individuals and organizations. The company has developed a nutrition management appliance designed to deliver personalized nutrient recommendations. This home appliance continuously analyzes health data to accurately assess the type and quantity of nutrients needed by users, allowing them to monitor and improve their health effectively. By leveraging advanced technology, AlgoCare aims to enhance nutritional awareness and support healthier lifestyle choices.

Mediquitous

Series D in 2024
Mediquitous is a natural health and beauty company that specializes in manufacturing a variety of skincare and food products. Their offerings include beauty patches, jelly food, and various healing items designed to help people improve their quality of life by maintaining their beauty effortlessly.

Easytem

Venture Round in 2024
Easytem is a manufacturing company that designs and develops medical devices to enhance skin and health in users.

StudyMax

Series C in 2024
StudyMax is a South Korean company that specializes in online English language learning for non-English speaking students. The company provides a comprehensive platform that includes various tools, tutorials, and study programs aimed at enhancing the learning experience. With 11 distinct learning processes and engaging elements such as interactive games and badges, StudyMax focuses on making language acquisition accessible and enjoyable. The Max online English learning program is compatible with both PCs and mobile devices, allowing users to learn at their convenience. Additionally, the application can be downloaded from the iTunes store, further broadening its accessibility. By leveraging advanced digital technologies, StudyMax aims to create a vibrant and interactive learning environment.

Novorex

Series A in 2023
Novorex is a biotechnology company focused on the development of small-molecule drugs aimed at treating oncology and neurological diseases. The company employs advanced technologies, including artificial intelligence, to enhance the efficiency of drug development. By integrating biophysical analysis with in vitro and in vivo assays, Novorex aims to create innovative therapeutic solutions for patients with cancer and central nervous system disorders. Through its research and development efforts, Novorex seeks to provide advanced treatment options that meet the needs of patients facing serious health challenges.

Getcha

Series B in 2023
Getcha is a comprehensive car purchasing and rental service that operates an online comparison shopping platform. The company facilitates the buying process by connecting consumers with sellers and providing access to a network of dealerships. Getcha enables users to obtain multiple price quotes, ensuring transparency in transaction pricing. In addition to car purchases, the company offers long-term rentals, leasing options, test rides, and car consulting services, catering to a wide range of automotive needs. By streamlining the car buying experience, Getcha empowers customers with the information they need to make informed decisions while allowing sellers to focus on motivated buyers.

CareMedi

Series B in 2023
CareMedi is a healthcare company specializing in the development of innovative medical devices, particularly a wearable drug pump designed to enhance the quality of life for individuals with diabetes. The company's platform offers a range of healthcare products, including medical equipment, nebulizers, aspirators, and massagers. By enabling consumers to conveniently order these products from home, CareMedi aims to improve overall lifestyle and health outcomes for its users.

Medipixel

Series B in 2023
Medipixel, Inc. is a South Korean MedTech startup founded in 2017, specializing in artificial intelligence-based diagnostic software and semi-autonomous robotic systems for lung cancer and cardiac interventions. The company is comprised of a team of AI experts in computer vision, deep learning, and reinforcement learning, collaborating with top healthcare professionals, including those at Seoul Asan Medical Center, to enhance disease diagnosis and surgical procedures. Medipixel offers three primary solutions for intervention surgeons: an AI-based diagnosis tool that assists in identifying lesions during coronary angiography, a guide and planning solution that visualizes coronary arteries to facilitate guidewire manipulation, and an automated navigation engine that directs robotic units through arteries with real-time commands. These innovations aim to improve surgical outcomes and patient safety by reducing reliance on contrast agents and enhancing the precision of interventions.

Velymonkeys

Series A in 2023
Blimonkids has created and run its own retail platform to aid the expansion of Korean cosmetics in India. In particular, it offers a one-stop service for the introduction of Korean beauty products into India, distribution, and sales, as well as marketing and sales, through its own mall, Maccaron.

Catch Table

Series D in 2023
Catch Table is a restaurant reservation management platform that offers a streamlined solution for booking tables in various dining establishments. It enables customers to make real-time reservations while filtering options based on specific criteria, including date, number of guests, price range, food category, and table type. Additionally, the platform provides useful information about amenities like valet parking and corkage services, enhancing the overall dining experience. By facilitating these features, Catch Table aims to simplify the reservation process for customers and improve operational efficiency for restaurants.

Gwanak Analog

Series A in 2023
Gwanak Analog is a company specializing in the design and supply of high-performance power and analog system-on-chip (SoC) and sensor products. It focuses on creating analog and power semiconductors for various applications, including industrial, telecommunications, automotive, and consumer sectors. By leveraging advanced power semiconductor design technology alongside digital signal processing techniques, Gwanak Analog aims to enhance power efficiency in its products. The company’s innovations help clients reduce overall energy consumption in their systems, providing environmentally sustainable and compact solutions.

Fadu

Venture Round in 2023
FADU Inc. is a fabless semiconductor company specializing in innovative memory and storage solutions. Established in 2015 and headquartered in Seoul, South Korea, with an additional office in Mountain View, California, FADU focuses on developing advanced Flash storage technology and architecture. The company's product lineup includes the FADU Annapurna and FADU Bravo SSD controllers, which are designed to meet the increasing data demands in enterprise data centers. With a team comprised of skilled architects, ASIC experts, and seasoned engineers from leading firms, FADU aims to introduce next-generation products that will redefine standards within the industry. As a newcomer in this competitive field, FADU is committed to leveraging innovative ideas to address the challenges posed by rapidly evolving data requirements.

Path

Venture Round in 2023
Path provides an AI platform for managing study habits. The startup employs deep learning-based to give non-face-to-face real-time academy lectures for middle and high schools, with the goal of changing the digital education platform.

TCELLOGY

Venture Round in 2023
Tcellogy is a biotechnology company focused on developing personalized cancer vaccines designed to stimulate T-cell responses against neoepitopes, which are unique to each patient's tumor. The company aims to enhance the quality of life for cancer patients by creating patient-specific vaccines that align with the principles of precision medicine. Tcellogy achieves this through the establishment of a comprehensive Omics-level database containing T cell-related information and by offering advanced neoantigen epitope prediction technology, which allows for more accurate targeting of cancer cells.

Novorex

Venture Round in 2023
Novorex is a biotechnology company focused on the development of small-molecule drugs aimed at treating oncology and neurological diseases. The company employs advanced technologies, including artificial intelligence, to enhance the efficiency of drug development. By integrating biophysical analysis with in vitro and in vivo assays, Novorex aims to create innovative therapeutic solutions for patients with cancer and central nervous system disorders. Through its research and development efforts, Novorex seeks to provide advanced treatment options that meet the needs of patients facing serious health challenges.

Boostimmune

Venture Round in 2023
Boostimmune is a biotech company focused on developing antibody-based therapies to address unmet needs in oncology by modulating the immune system. The company is dedicated to overcoming challenges in cancer treatment through innovative anti-cancer therapies that enhance the human immune response. Boostimmune specializes in the research and development of immuno-oncology drugs, including inhibitors targeting myeloid-derived suppressor cells (MDSCs), which play a role in suppressing immune action against cancer cells within the tumor microenvironment. By increasing the frequency and activity of T cells, Boostimmune aims to improve the effectiveness of cancer treatments and ultimately facilitate the destruction of cancer cells. The company is driven by a team of industry experts committed to advancing cancer therapy solutions.

Likey

Venture Round in 2023
Likey develops a platform for creators to connect with fans. The platform of the company provides monthly membership payments, a fan-exclusive community, an online class/seminar, customized content, and live video fan meetings, allowing customers to be social and meet their admirers.

Illimis Therapeutics

Venture Round in 2023
Illimis Therapeutics is a biotech company focused on developing innovative treatments for neurodegenerative diseases, particularly Alzheimer's disease. Utilizing a chimeric fusion protein platform, the company aims to address the significant medical needs associated with degenerative brain conditions. By specializing in fusion protein technology, Illimis Therapeutics seeks to offer new therapeutic modalities that enhance patient care and improve outcomes in the healthcare industry.

S&E bio

Series A in 2022
S&E Bio is a biopharmaceutical company specializing in the development of cell therapies aimed at addressing neurological disorders. The company focuses on creating safe and effective treatments using stem cell-derived extracellular vesicles, particularly mesenchymal stem cell-derived therapeutics. S&E Bio targets a range of conditions, including acute stroke, moyamoya disease, chronic stroke, dementia, and cognitive disorders. Through its innovative approach to stem cell therapy, the company seeks to provide advanced treatment options for patients suffering from these incurable diseases, enhancing their quality of life and treatment outcomes.

S&E bio

Venture Round in 2022
S&E Bio is a biopharmaceutical company specializing in the development of cell therapies aimed at addressing neurological disorders. The company focuses on creating safe and effective treatments using stem cell-derived extracellular vesicles, particularly mesenchymal stem cell-derived therapeutics. S&E Bio targets a range of conditions, including acute stroke, moyamoya disease, chronic stroke, dementia, and cognitive disorders. Through its innovative approach to stem cell therapy, the company seeks to provide advanced treatment options for patients suffering from these incurable diseases, enhancing their quality of life and treatment outcomes.

Imagoworks

Series B in 2022
Imagoworks offers a Web-based dental CAD solution using AI, streamlining the digital workflow for dental professionals. Imagoworks currently offers Dentbird Crown, which automatically generates optimal crown designs with a single click and without any software installation required.

Balaan

Series C in 2022
Balaan operates an online marketplace specializing in luxury goods, offering a diverse selection of multi-branded fashion products, including clothing, accessories, and jewelry from renowned luxury brands. The platform distinguishes itself by providing customers with the latest luxury items delivered within three days, facilitated through contracts with local boutiques in Europe. By leveraging this network, Balaan enables consumers to access premium fashion at more affordable prices compared to traditional overseas purchasing methods. The company aims to make luxury shopping more accessible and convenient for both men and women.

Select Star

Series A in 2022
Select Star is a data platform for AI technology that offers dataset building, storage, and analysis services.

Datumo

Series A in 2022
Datumo, formerly known as SelectStar Inc., specializes in a cloud-based artificial intelligence data production platform. The company has developed an application called Cash Mission, which collects and analyzes data while rewarding users for their contributions. By connecting corporate clients with a network of crowd-workers, Datumo aims to address the challenges of obtaining accurate data for AI applications. The platform not only facilitates this connection but also emphasizes the importance of quality and cost-efficiency in data production. Founded in 2018 and headquartered in South Korea, Datumo continues to innovate in the field of mobile crowd-sourcing to enhance data collection processes for enterprises.

Fainders.AI

Series A in 2022
Fainders.AI is a technology company specializing in computer vision solutions for unmanned retail environments. They focus on creating a checkout-free shopping experience that enhances convenience for customers while simultaneously boosting profitability for store owners and distributors. By leveraging artificial intelligence, Fainders.AI offers retail automation solutions that eliminate the need for costly sensor-based hardware installations. Their innovative approach aims to transform traditional offline stores into automated spaces, addressing the challenges associated with modern retail operations.

LUNASOFT

Venture Round in 2022
LUNASOFT INC. is a South Korean company founded in 2016, specializing in the development of chatbots and integrated management platforms aimed at enhancing customer support. The company offers a range of solutions, including Luna Plus, a courier exchange platform; Luna Plus Mobile, which facilitates real-time business consultations; and Luna Plus CTI, a customer counseling platform that combines phone and intelligent chat counseling. Additionally, LUNASOFT develops customer consultation chatbots tailored for popular messaging platforms such as Naver and Kakao, primarily catering to e-commerce businesses. Based in Seoul, LUNASOFT is focused on providing innovative chat solutions to improve customer interaction and support processes.

Coinvestor

Series A in 2022
To be the world’s most engaging investment platform for digital assets, Coinvestor provides an interactive digital space for investors and traders seeking profit-making opportunities from digital assets through a seamless and secure service. Coinvestor believes that running a transparent operation, enhancing investment processes, and creating a collaborative environment set it apart from other crypto-investment platforms. On Coinvestor, all crypto-market players can access insights, share strategies, and monetize expertise, feeling assured at any time. Join us in building this journey.

BC Labs

Series A in 2022
BC Labs is a blockchain development and crypto investment banking company that specializes in creating innovative investment strategies. It has developed a strategy-building platform that facilitates an accessible cryptocurrency investment strategy marketplace. This platform allows users to purchase and implement trading strategies crafted by investment experts within the highly volatile digital asset market. By enabling blockchain and crypto traders to clone and refine these strategies, BC Labs aims to enhance the trading experience and provide valuable insights into the digital asset investment landscape.

Innospace

Series B in 2022
Innospace Co Ltd is an aerospace and defense company that specializes in the development and provision of launch services for small satellites. The company focuses on creating hybrid rocket-powered small satellite launch vehicles, which are designed to deliver low-cost, low-latency, and eco-friendly launch solutions. By leveraging innovative technology, Innospace aims to establish a reliable presence in the small satellite market, offering services that meet the growing demands of satellite deployment while emphasizing sustainable practices.

Jaranda

Series B in 2022
Jaranda Co., Ltd., headquartered in Seoul, South Korea, operates a digital platform that bridges the gap between teachers, parents, and students. The company's core business is to facilitate access to childcare and education services, addressing the challenge of information asymmetry in this sector. Jaranda's platform employs analytics to match students with compatible teachers, offers regular visit services, and provides lifecycle management, ensuring children and pre-teens receive appropriate education in a convenient manner.

Catch Table

Series C in 2022
Catch Table is a restaurant reservation management platform that offers a streamlined solution for booking tables in various dining establishments. It enables customers to make real-time reservations while filtering options based on specific criteria, including date, number of guests, price range, food category, and table type. Additionally, the platform provides useful information about amenities like valet parking and corkage services, enhancing the overall dining experience. By facilitating these features, Catch Table aims to simplify the reservation process for customers and improve operational efficiency for restaurants.

Spark Biopharma

Series C in 2022
SPARK BioPharma Co., Ltd. was established in Seoul National University in January 2016 based on the unique drug molecule diversity technology, the image-based screening technology using the unique fluorescent skeleton probe, and the target protein identification technology in the initial drug development stage. We are currently exploring and developing new drug candidates using these three core technologies, and we will continue to accelerate the development of new drugs and increase the success rate through strategic cooperation research with domestic and overseas research institutes and pharmaceutical institutions. '

Daan Biotherapeutics

Seed Round in 2022
DAAN Biotherapeutics is a biopharmaceutical company focused on developing innovative treatments for cancer patients. The company specializes in research and development in the field of cancer therapies, employing a range of approaches such as cell therapies, antibodies, and small molecule inhibitors. DAAN Biotherapeutics is particularly dedicated to immune-oncology, utilizing anticancer immune cell therapies, including natural killer (NK) cells and T cell receptors. Through its independent research infrastructure, the company conducts clinical trials to explore various treatment strategies, aiming to create effective new drugs, particularly for lung cancer. By providing healthcare providers with advanced therapeutic options, DAAN Biotherapeutics seeks to improve outcomes for cancer patients.

Daim Research

Seed Round in 2022
Daim Research is a technology company specializing in AI-based automation solutions for logistics and manufacturing sectors. They develop software that manages and optimizes the operation of cluster logistics robots using collaborative intelligence technology, ensuring peak performance and facilitating innovative manufacturing processes driven by data and artificial intelligence.

KaliVir Immunotherapeutics

Series A in 2022
KaliVir Immunotherapeutics is a biopharmaceutical company focused on developing innovative oncolytic viral immunotherapy products aimed at treating various tumor types. Utilizing a next-generation vaccinia platform, KaliVir enhances systemic delivery capabilities, enabling targeted replication and spread of the virus within the tumor microenvironment. The company’s approach integrates technologies both developed in-house and licensed from the University of Pittsburgh, leveraging cutting-edge research in oncolytic viruses and immunotherapy. With a focus on tailored transgene programs, KaliVir offers healthcare professionals powerful tools designed to improve the effectiveness of cancer treatments through its proprietary genetic modifications.

OncXerna Therapeutics

Venture Round in 2022
OncXerna Therapeutics, Inc. is a biotechnology company focused on developing precision medicines for cancer patients by utilizing an RNA-based biomarker platform. The company aims to improve patient outcomes by prospectively identifying individuals based on the unique RNA biology of their tumor microenvironments. This innovative approach enables OncXerna to match patients with targeted oncology therapies that correspond to their specific tumor characteristics. Founded in 2018 and based in Waltham, Massachusetts, with an additional location in Shanghai, China, OncXerna was formerly known as Oncologie, Inc. and changed its name in September 2020 to reflect its commitment to advancing next-generation precision medicine for a broader range of cancer patients.

Neosapience

Series B in 2022
Neosapience, Inc. is a South Korean company specializing in artificial intelligence-driven voice synthesis and avatar technologies. Founded in 2017 and headquartered in Seoul, the company has developed innovative products like Icepeak.AI and Typecast, which allow users to generate speech that closely mimics individual voice characteristics, including prosody and emotion. Icepeak.AI is an online platform that learns and replicates voice features, while Typecast, launched in 2019, has gained popularity as an AI-powered content creation service, used by over 2 million users across 225 countries. Additionally, Neosapience offers a mobile application, ICEPEAK, enabling users to create personalized voice interactions. The company aims to redefine content creation through advanced AI technologies, making voice-over processes more accessible and efficient.

HITS

Series A in 2022
HITS is a biotech company that creates digital solutions to accelerate drug development and introduce a new drug discovery paradigm. The company creates a cloud-based drug development platform that connects AI models with docking and molecular dynamics.

Rapport Labs

Series B in 2022
Rapport Labs is a company that specializes in enhancing the online shopping experience, particularly in the fashion industry. They have developed an application called 4050 Fashion, which caters specifically to women by offering a wide range of clothing options from well-known brands for different age groups. The platform provides discounts and features a customer experience team that offers real-time fashion advice through phone calls and inquiries, ensuring users can easily find and purchase their desired apparel online.

Organoid Sciences

Series B in 2022
Organoid Sciences is a biotechnology company founded in 2018 and located in Seongnam-si, South Korea. The company specializes in developing organoid-based therapies using its proprietary Keo cannabinoid technology to address various incurable diseases. In addition to drug development, Organoid Sciences provides drug screening services and focuses on regenerative medicine, aiming to advance treatment options through innovative approaches.

Amicogen

Post in 2022
Amicogen is an industrial biotechnology company based in Korea, specializing in the development, production, and distribution of bioproducts and health functional food ingredients. The company's diverse product portfolio includes special enzymes, N-acetylglucosamine, pinitol, D-Chiro-inositol, collagen peptides, and protein A chromatography resins. Additionally, Amicogen offers products such as endo-lac, ginseng extraction powder, cauliflower mushrooms, chitosan oligosaccharides, chitoslim, and keyclean, catering to the growing demand for innovative solutions in the health and wellness sectors.

Rapport Labs

Venture Round in 2022
Rapport Labs is a company that specializes in enhancing the online shopping experience, particularly in the fashion industry. They have developed an application called 4050 Fashion, which caters specifically to women by offering a wide range of clothing options from well-known brands for different age groups. The platform provides discounts and features a customer experience team that offers real-time fashion advice through phone calls and inquiries, ensuring users can easily find and purchase their desired apparel online.

ViFiVE

Venture Round in 2022
ViFiVE is a software development company that specializes in creating digital health solutions, particularly for musculoskeletal disorders. The company has recently launched its patient app, which allows users to perform self-assessments of their health issues and monitor therapeutic outcomes remotely. Through its AI-driven technology, ViFiVE provides a comprehensive digital interface that empowers users to track their health parameters and maintain a quality lifestyle. The platform aims to enhance compliance with treatment protocols and improve overall health management. An online inquiry form is available on the company's website for interested users.

Tcino Bioscience

Venture Round in 2022
Tcino Bioscience develops molecule anti-cancer drugs for cancer patients.

Cinamon

Venture Round in 2022
Cinamon provides a visual story platform designed for casual games. In 2018, the company began as a joint venture with Naver Webtoon. Since our first project, an interactive stories app called "Maybe," the company has continued to broaden its scope in the field of visual storytelling. The company is currently working on two projects: a 2D and a 3D UGC story platform.

Anterogen

Post in 2022
Anterogen is a bio-venture company focused on the research and development of cell therapy products and orphan drugs utilizing adult stem cells. The company has developed several products, including Cupistem injection, Queen cell, Remodulin injection, and TheraStem-Derma. In addition to its product offerings, Anterogen provides cell banking services and analytical services, which encompass sample analysis for clinical studies. Through its innovative approach, Anterogen aims to advance therapeutic options in the field of regenerative medicine.

Markoville

Venture Round in 2022
Markoville is an entertainment content company that creates a character for animation, game, and comics.

HITS

Venture Round in 2022
HITS is a biotech company that creates digital solutions to accelerate drug development and introduce a new drug discovery paradigm. The company creates a cloud-based drug development platform that connects AI models with docking and molecular dynamics.

StyleC

Series B in 2021
StyleC is an online marketplace that provides a diverse range of products for personal and home use. The platform features an extensive selection of items across various categories, including furniture, books, clothing, cosmetics, and accessories. By offering this wide array of consumer goods, StyleC enables customers to conveniently purchase products that suit their preferences and needs.

Path

Seed Round in 2021
Path provides an AI platform for managing study habits. The startup employs deep learning-based to give non-face-to-face real-time academy lectures for middle and high schools, with the goal of changing the digital education platform.

Nota AI

Series B in 2021
Nota AI is a technology startup specializing in the optimization of artificial intelligence models. The company has developed NetsPresso, a proprietary hardware-aware optimization platform designed to streamline the development process, significantly reducing the time and resources needed to create AI models. This platform allows for the customization of AI solutions tailored to specific devices, making it applicable across various industries, including intelligent transportation systems and low-powered driver monitoring systems. By focusing on the intersection of hardware and AI, Nota AI enables organizations to implement advanced technologies more efficiently and effectively.

WAUG

Series C in 2021
WAUG Travel Inc. is a prominent online reservation platform that facilitates the booking of tours and activities for travelers worldwide. The platform allows users to easily search for, compare prices, and check availability for a variety of experiences, including museum visits, theme park outings, and adventure activities. By streamlining the process of creating travel itineraries, WAUG enhances the travel experience, enabling users to discover and engage with new destinations effectively.

Getcha

Series A in 2021
Getcha is a comprehensive car purchasing and rental service that operates an online comparison shopping platform. The company facilitates the buying process by connecting consumers with sellers and providing access to a network of dealerships. Getcha enables users to obtain multiple price quotes, ensuring transparency in transaction pricing. In addition to car purchases, the company offers long-term rentals, leasing options, test rides, and car consulting services, catering to a wide range of automotive needs. By streamlining the car buying experience, Getcha empowers customers with the information they need to make informed decisions while allowing sellers to focus on motivated buyers.

Balaan

Series B in 2021
Balaan operates an online marketplace specializing in luxury goods, offering a diverse selection of multi-branded fashion products, including clothing, accessories, and jewelry from renowned luxury brands. The platform distinguishes itself by providing customers with the latest luxury items delivered within three days, facilitated through contracts with local boutiques in Europe. By leveraging this network, Balaan enables consumers to access premium fashion at more affordable prices compared to traditional overseas purchasing methods. The company aims to make luxury shopping more accessible and convenient for both men and women.

afun interactive

Series B in 2021
Afun Interactive Inc. is a virtual reality company based in Seoul, South Korea, founded in 2016 by Han Yu. The company specializes in three-dimensional rendering technologies and focuses on the production and distribution of real-time content for various applications, including augmented reality and virtual reality. Afun Interactive creates digital content tailored to the specific needs of its clients, serving the entertainment industry by providing high-quality animations and graphics for movies and games. Through its innovative approach, the company aims to deliver immersive experiences and enhance the visual storytelling capabilities of its partners.

Bankware Global

Series B in 2021
Founded in 2010 and headquartered in Seoul, Korea, Bankware Global specializes in the development of banking and financial software systems tailored for various sectors, including retail, corporate, private, treasury, and microfinance banks. With a presence in three countries and four offices, the company serves over 100 financial institutions across seven countries in the Asia Pacific region. Bankware Global is recognized for its expertise in core banking solutions, having supplied its software to five digital banks in markets such as Korea, China, Japan, and Taiwan. The company is distinguished as a leading provider of core banking solutions in Korea, focusing on delivering innovative financial institution products and transaction software to both domestic and international clients.

Upstage

Series A in 2021
Upstage AI is a startup that specializes in providing customized artificial intelligence services to businesses. The company develops tailored AI models designed to address specific challenges faced by its clients, thereby enhancing operational efficiency and fostering innovation. By enabling organizations to focus on their core tasks, Upstage AI helps them leverage AI technology to solve problems and advance their business processes effectively.

WAVEPIA

Series A in 2021
WAVEPIA is a semiconductor manufacturing company.

Tcino Bioscience

Series A in 2021
Tcino Bioscience develops molecule anti-cancer drugs for cancer patients.

J2H Biotech

Venture Round in 2021
J2H Biotech is a bio-venture company dedicated to the development of small-molecule drugs aimed at treating rare and intractable diseases. The company specializes in creating synthetic medications that enhance oral absorption rates and employs patented systems to facilitate the availability of generic drugs for conditions such as rare diseases, infectious diseases, and liver diseases. By focusing on these innovative approaches, J2H Biotech seeks to provide healthcare professionals with differentiated therapeutic options that can improve patient outcomes and contribute to overall public health.

Return Zero

Series B in 2021
Return Zero, Inc. is a technology company based in Seoul, South Korea, founded in 2011. It specializes in developing an artificial intelligence-based voice recognition application that transforms phone conversations into text messages. The company's innovative application converts audio phone messages into messenger text, facilitating seamless communication. With a focus on advanced speech recognition and machine learning, Return Zero aims to enhance the accessibility and usability of voice interactions in digital messaging.

Pharos iBio

Series C in 2021
Pharos iBio Co. is a company focused on the development of innovative treatments for rare and intractable diseases. Utilizing a cutting-edge drug development platform that incorporates big data and artificial intelligence, Pharos iBio aims to address significant unmet medical needs. The company’s product pipeline includes several candidate drugs, such as PHI-101-AML for refractory or relapsed acute myeloid leukemia, PHI-101-OC for platinum-resistant or refractory ovarian cancer, and PHI-101-TNBC for metastatic triple-negative breast cancer. Additionally, Pharos iBio is advancing other candidates, including PHI-201, PHI-301, and PHI-501, as part of its commitment to improving patient outcomes in challenging therapeutic areas.

Rapport Labs

Series A in 2021
Rapport Labs is a company that specializes in enhancing the online shopping experience, particularly in the fashion industry. They have developed an application called 4050 Fashion, which caters specifically to women by offering a wide range of clothing options from well-known brands for different age groups. The platform provides discounts and features a customer experience team that offers real-time fashion advice through phone calls and inquiries, ensuring users can easily find and purchase their desired apparel online.

Rapport Labs

Series A in 2021
Rapport Labs is a company that specializes in enhancing the online shopping experience, particularly in the fashion industry. They have developed an application called 4050 Fashion, which caters specifically to women by offering a wide range of clothing options from well-known brands for different age groups. The platform provides discounts and features a customer experience team that offers real-time fashion advice through phone calls and inquiries, ensuring users can easily find and purchase their desired apparel online.

Kmong

Series C in 2021
Kmong Inc. is a South Korean company that operates a freelance and micro-job marketplace, facilitating the exchange of services between individuals. Established in June 2012, the platform allows users to buy and sell a wide range of services across various categories, including design, IT and programming, marketing, consulting, translation, writing, and more. Freelancers can list their services with price quotes, making it easier for potential clients to find and engage with them. Kmong's services extend beyond traditional categories to include offerings like private lessons and unique personal services. The company is based in Seoul and provides a mobile application for Android devices, enhancing accessibility for users.

Databank

Series A in 2021
Databank is an AI-based EdTech startup that focuses on enhancing educational outcomes through innovative technology. The company addresses the knowledge gap in education by offering online test preparation services for students. Utilizing AI-powered solutions, Databank evaluates open-ended responses and delivers personalized instruction tailored to individual learning needs. Through its application of machine learning and deep learning techniques, the firm develops strategies and tools aimed at improving the effectiveness of educational assessments and instruction.

Databank

Series A in 2021
Databank is an AI-based EdTech startup that focuses on enhancing educational outcomes through innovative technology. The company addresses the knowledge gap in education by offering online test preparation services for students. Utilizing AI-powered solutions, Databank evaluates open-ended responses and delivers personalized instruction tailored to individual learning needs. Through its application of machine learning and deep learning techniques, the firm develops strategies and tools aimed at improving the effectiveness of educational assessments and instruction.

Pin Therapeutics

Venture Round in 2021
Pin Therapeutics, Inc. is a biotechnology company founded in February 2017 and headquartered in South San Francisco, California. The company is focused on developing therapeutic products that harness protein degradation technology to target immune diseases, cancer, and aging-related conditions. Pin Therapeutics employs advanced screening systems, including its PinE3 platform for E3 ligase identification and the PinGLUE system for molecular glue degrader discovery. With a diverse team comprising experienced professionals from global pharmaceutical and biotech sectors, the company is actively advancing several programs, including selective molecular glue degraders and a PROTAC program. Through its innovative approaches to drug discovery, Pin Therapeutics aims to address critical unmet medical needs while enhancing the efficiency and specificity of protein degradation in therapeutic contexts.

Zymedi

Venture Round in 2021
Zymedi is a pharmaceutical company dedicated to developing innovative therapeutics for life-threatening diseases. Its primary focus is on aminoacyl-tRNA synthetases, targeting conditions such as pulmonary arterial hypertension and liver fibrosis. By leveraging its novel therapeutics platform, Zymedi aims to enhance the quality of life for patients by facilitating quicker access to treatment, ultimately leading to improved medical outcomes.

Innovo Therapeutics

Venture Round in 2021
Innovo Therapeutics is a biotechnology company focused on drug research and development through its proprietary artificial intelligence platform, DeepZema. This platform enhances the drug discovery process by integrating real-time data from practical drug development with virtual methodologies, utilizing machine learning for target identification and toxicity prediction. Innovo Therapeutics aims to discover new therapeutic options that improve the quality of human life, particularly addressing conditions related to fibrosis, immune, and inflammatory diseases.

TCUBEit

Venture Round in 2021
TCUBEit Inc. is a biotechnology company based in Sejong, South Korea, with an additional location in Cheongju. Founded in 2019, TCUBEit specializes in T cell-based immunotherapy, focusing on the collection and organization of T cells from patients. The company is dedicated to enhancing both the quantity and quality of T cells, which play a crucial role in identifying and eliminating cancers and infections within the human body. Through its research and product development efforts, TCUBEit aims to advance the discovery and commercialization of personalized therapeutic cell-based therapies, contributing to the field of cancer immunotherapy.

S&E bio

Venture Round in 2021
S&E Bio is a biopharmaceutical company specializing in the development of cell therapies aimed at addressing neurological disorders. The company focuses on creating safe and effective treatments using stem cell-derived extracellular vesicles, particularly mesenchymal stem cell-derived therapeutics. S&E Bio targets a range of conditions, including acute stroke, moyamoya disease, chronic stroke, dementia, and cognitive disorders. Through its innovative approach to stem cell therapy, the company seeks to provide advanced treatment options for patients suffering from these incurable diseases, enhancing their quality of life and treatment outcomes.

Prazer Therapeutics

Venture Round in 2021
Prazer Therapeutics is a biotechnology company dedicated to developing novel therapeutics for patients suffering from intractable diseases, particularly neurodegenerative and refractory inflammatory conditions. The company employs innovative drug design methodologies, including rational molecular drug design and next-generation protein degradation technology, to create effective treatments. By focusing on areas of unmet medical need, Prazer Therapeutics aims to advance drug development and provide solutions for diseases that currently lack effective therapies.

Promedigen

Venture Round in 2021
Promedigen is a biotechnology company dedicated to the treatment of cancer and neurodegenerative disorders. It specializes in customized modified protein technology, which facilitates the production of abnormally modified proteins linked to various serious diseases. This innovative approach enables healthcare professionals to more effectively address conditions such as cancer and dementia, thereby advancing therapeutic options in these critical areas of medicine.

Watcha

Venture Round in 2020
WATCHA, Inc. is a South Korean company founded in 2011 and headquartered in Seoul, specializing in online interactive media services. It initially gained popularity as a movie review application, becoming a favorite in Korea for its personalized recommendation technology. Users rate movies, allowing WATCHA to predict their preferences for unseen films. In addition to its review platform, WATCHA launched a subscription video-on-demand service called WATCHA PLAY in 2016, which offers a wide selection of movies and TV series accessible across various devices, including web browsers, mobile platforms, and smart TVs. The service is noted for its highly accurate content recommendations, with a significant portion of consumed content driven by these suggestions. WATCHA has also expanded its presence internationally, having launched in Japan in 2015.

HaplnScience

Seed Round in 2020
HaplnScience is a pharmaceutical company established in 2018 and based in Seongnam-si, Gyeonggi-do, South Korea. The company specializes in developing innovative anti-aging therapies aimed at reversing tissue and organ degeneration. Utilizing HAPLN1, a novel protein, HaplnScience's research focuses on strengthening the extracellular matrix to halt the aging process. Their drug formulations are designed to prevent the degeneration of bodily tissues, effectively addressing issues such as skin aging, hair aging, and osteoarthritis. By advancing these therapeutic solutions, HaplnScience aims to significantly enhance the health and quality of life for the elderly.

CHAI

Series B in 2020
CHAI is a company focused on developing infrastructure technologies aimed at enhancing the efficiency of the digital economy. It offers a fintech platform that includes a debit card, a merchant-facing payment API, and an e-wallet that utilizes blockchain technology. This platform allows merchants and individual users to integrate a diverse array of payment options quickly and easily, often in less than an hour. Users can pay for items online by linking their bank accounts, streamlining the payment process. Through its innovative solutions, CHAI aims to facilitate seamless financial transactions and improve the overall digital payment landscape.

MediBloc

Series A in 2020
MediBloc Co., Ltd., established in 2017 and headquartered in Gibraltar, specializes in developing and operating a blockchain-based digital healthcare information platform. This platform facilitates secure and efficient exchange of electronic health records between medical institutions, empowers individuals with control over their personal health records, and enables personalized precision medical services. It serves patients, healthcare providers, medical institutions, and researchers, fostering a decentralized ecosystem for medical data sharing and utilization.

Olix Pharmaceuticals

Post in 2020
OliX Pharmaceuticals, Inc. is a clinical-stage biotechnology company based in Suwon, South Korea, dedicated to developing RNA interference (RNAi) therapeutics targeting various dermal, ophthalmic, and pulmonary diseases. The company’s product pipeline includes OLX101 for skin scarring, OLX102 for skin whitening, OLX103 for atopic dermatitis, OLX104 for hair loss, OLX105 for anti-wrinkle treatments, and OLX106 for diabetic foot ulcers. Additionally, it is developing OLX301 for age-related macular degeneration, OLX304 for retinitis pigmentosa, OLX201 for lung fibrosis, OLX202 for asthma, OLX203 for influenza, OLX401 for neuropathic pain, OLX701 for liver fibrosis, and OLX701 for cancer immunotherapy. The company has also entered into a collaboration agreement with Théa to advance SiRNA therapeutics for ophthalmic conditions. Founded in 2010, OliX Pharmaceuticals leverages its proprietary RNAi technology to regulate the expression of genes associated with various diseases.

My Franchise

Series A in 2020
My Franchise is a company founded in 2019 in Seoul, South Korea, that focuses on bridging the gap between franchise headquarters and prospective founders. It has developed an online platform that serves as a resource for these two parties, facilitating a partnership that is mutually beneficial. The platform provides valuable startup information, such as the number of franchisees over the years, average sales figures, and the associated startup costs of domestic franchise brands. This allows prospective founders to effectively compare and analyze important brand information, categorized by industry, helping them make informed decisions in their franchise endeavors.

Wave

Series B in 2020
Wave Corporation, founded in 2018 and based in South Korea, develops a mobile video chat application designed to enhance social interactions among users. The application enables individuals to create chat rooms where they can engage in group video chats, play live party games, watch video clips, read webtoons, and share photos. By facilitating these activities, Wave aims to reduce the distance between people, allowing friends to connect and interact in a more engaging and entertaining manner.

Innospace

Series A in 2020
Innospace Co Ltd is an aerospace and defense company that specializes in the development and provision of launch services for small satellites. The company focuses on creating hybrid rocket-powered small satellite launch vehicles, which are designed to deliver low-cost, low-latency, and eco-friendly launch solutions. By leveraging innovative technology, Innospace aims to establish a reliable presence in the small satellite market, offering services that meet the growing demands of satellite deployment while emphasizing sustainable practices.

Cimplrx

Series A in 2020
Cimplrx is a health technology company specializing in drug discovery through the use of explainable artificial intelligence. The company has developed a platform that facilitates the discovery and development of drug candidates by providing comprehensive information on both new findings and existing drugs available in the market. Its database includes detailed data on various drugs, including their structure, categories, and technical validation. This technology enables clients to access essential tools for business model formation while also allowing for the analysis and visualization of the drug discovery process, thus enhancing decision-making and innovation in the pharmaceutical sector.

Immunobiome

Series A in 2020
Immunobiome is a biotechnology company focused on developing microbiome-based therapeutics aimed at treating challenging diseases, including cancer, autoimmune disorders, allergies, and neurological conditions. By leveraging advanced immunology, bioinformatics, and fundamental microbiome research, the company seeks to create innovative solutions that address conditions often deemed incurable. Its platform specializes in targeted treatments that can help manage intractable immune-related diseases and improve patient outcomes in various health challenges, including organ transplant rejections and inflammation-related issues.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.